Literature DB >> 9007991

gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.

S Gillis1, B C Furie, B Furie, H Patel, M C Huberty, M Switzer, W B Foster, H A Scoble, M D Bond.   

Abstract

The gamma-carboxyglutamic acid (Gla) domains of the vitamin K-dependent blood coagulation proteins contain 10 highly conserved Gla residues within the first 33 residues, but factor IX is unique in possessing 2 additional Gla residues at positions 36 and 40. To determine their importance, factor IX species lacking these Gla residues were isolated from heterologously expressed human factor IX. Using ion-exchange chromatography, peptide mapping, mass spectrometry, and N-terminal sequencing, we have purified and identified two partially carboxylated recombinant factor IX species; factor IX/gamma 40E is uncarboxylated at residue 40 and factor IX/gamma 36,40E is uncarboxylated at both residues 36 and 40. These species were compared with the fully gamma-carboxylated recombinant factor IX, unfractionated recombinant factor IX, and plasma-derived factor IX. As monitored by anti-factor IX:Ca (II)-specific antibodies and by the quenching of intrinsic fluorescence, all these factor IX species underwent the Ca(II)-induced conformational transition required for phospholipid membrane binding and bound equivalently to phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Endothelial cell binding was also similar in all species, with half-maximal inhibition of the binding of 125I-labeled plasma-derived factor IX at concentrations of 2-6 nM. Functionally, factor IX/gamma 36,40E and factor IX/gamma 40E were similar to fully gamma-carboxylated recombinant factor IX and plasma-derived factor IX in their coagulant activity and in their ability to participate in the activation of factor X in the tenase complex both with synthetic phospholipid vesicles and activated platelets. However, Gla 36 and Gla 40 represent part of the epitope targeted by anti-factor IX:Mg(II)-specific antibodies because these antibodies bound factor IX preferentially to factor IX/gamma 36,40E and factor IX/gamma 40E. These results demonstrate that the gamma-carboxylation of glutamic acid residues 36 and 40 in human factor IX is not required for any function of factor IX examined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9007991      PMCID: PMC2143515          DOI: 10.1002/pro.5560060121

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  39 in total

1.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

2.  A simple method for the preparation of homogeneous phospholipid vesicles.

Authors:  Y Barenholz; D Gibbes; B J Litman; J Goll; T E Thompson; R D Carlson
Journal:  Biochemistry       Date:  1977-06-14       Impact factor: 3.162

3.  The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin.

Authors:  G L Nelsestuen; T H Zytkovicz; J B Howard
Journal:  J Biol Chem       Date:  1974-10-10       Impact factor: 5.157

4.  Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX.

Authors:  S J Freedman; M D Blostein; J D Baleja; M Jacobs; B C Furie; B Furie
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

5.  Vitamin K dependent modifications of glutamic acid residues in prothrombin.

Authors:  J Stenflo; P Fernlund; W Egan; P Roepstorff
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

6.  A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

Authors:  R G Di Scipio; M A Hermodson; S G Yates; E W Davie
Journal:  Biochemistry       Date:  1977-02-22       Impact factor: 3.162

7.  Beta-hydroxyaspartic acid in vitamin K-dependent proteins.

Authors:  P Fernlund; J Stenflo
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

8.  Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX.

Authors:  W F Cheung; A S Wolberg; D W Stafford; K J Smith
Journal:  Thromb Res       Date:  1995-12-01       Impact factor: 3.944

9.  Role of gamma-carboxyglutamic acid. Cation specificity of prothrombin and factor X-phospholipid binding.

Authors:  G L Nelsestuen; M Broderius; G Martin
Journal:  J Biol Chem       Date:  1976-11-25       Impact factor: 5.157

10.  Activation of factor VIII by factor IXa.

Authors:  M E Rick
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

View more
  10 in total

1.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Authors:  Henrik Østergaard; Jais R Bjelke; Lene Hansen; Lars Christian Petersen; Anette A Pedersen; Torben Elm; Flemming Møller; Mette B Hermit; Pernille K Holm; Thomas N Krogh; Jørn M Petersen; Mirella Ezban; Brit B Sørensen; Mette D Andersen; Henrik Agersø; Haleh Ahmadian; Kristoffer W Balling; Marie Louise S Christiansen; Karin Knobe; Timothy C Nichols; Søren E Bjørn; Mikael Tranholm
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

3.  Quantifying vitamin K-dependent holoprotein compaction caused by differential γ-carboxylation using high-pressure size exclusion chromatography.

Authors:  Nicholas C Vanderslice; Amanda S Messer; Kanagasabai Vadivel; S Paul Bajaj; Martin Phillips; Mostafa Fatemi; Weijie Xu; William H Velander
Journal:  Anal Biochem       Date:  2015-03-22       Impact factor: 3.365

Review 4.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

5.  Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Glycobiology       Date:  2008-05-02       Impact factor: 4.313

6.  Coagulation Factor IX for Hemophilia B Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov
Journal:  Acta Naturae       Date:  2012-04       Impact factor: 1.845

7.  Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin.

Authors:  Jianming Liu; Anna Jonebring; Jonas Hagström; Ann-Christin Nyström; Ann Lövgren
Journal:  Protein J       Date:  2014-04       Impact factor: 2.371

8.  Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product.

Authors:  Lucia F Zacchi; Dinora Roche-Recinos; Cassandra L Pegg; Toan K Phung; Mark Napoli; Campbell Aitken; Vanessa Sandford; Stephen M Mahler; Yih Yean Lee; Benjamin L Schulz; Christopher B Howard
Journal:  Commun Biol       Date:  2021-03-23

9.  Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.

Authors:  Jianguo Zhao; Weijie Xu; Jason W Ross; Eric M Walters; Stephen P Butler; Jeff J Whyte; Lindsey Kelso; Mostafa Fatemi; Nicholas C Vanderslice; Keith Giroux; Lee D Spate; Melissa S Samuel; Cliff N Murphy; Kevin D Wells; Nick C Masiello; Randall S Prather; William H Velander
Journal:  Sci Rep       Date:  2015-09-21       Impact factor: 4.379

10.  Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

Authors:  Dougald M Monroe; Richard J Jenny; Kevin E Van Cott; Shelly Buhay; Laura L Saward
Journal:  Adv Hematol       Date:  2016-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.